Revelation Biosciences (REVB) Competitors $0.29 -0.02 (-7.82%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends REVB vs. SYRS, GTBP, CNSP, HOTH, PPBT, ELAB, CANF, IMCC, AEZS, and BMRAShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Syros Pharmaceuticals (SYRS), GT Biopharma (GTBP), CNS Pharmaceuticals (CNSP), Hoth Therapeutics (HOTH), Purple Biotech (PPBT), Elevai Labs (ELAB), Can-Fite BioPharma (CANF), IM Cannabis (IMCC), Aeterna Zentaris (AEZS), and Biomerica (BMRA). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Syros Pharmaceuticals GT Biopharma CNS Pharmaceuticals Hoth Therapeutics Purple Biotech Elevai Labs Can-Fite BioPharma IM Cannabis Aeterna Zentaris Biomerica Syros Pharmaceuticals (NASDAQ:SYRS) and Revelation Biosciences (NASDAQ:REVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, community ranking, profitability and institutional ownership. Does the MarketBeat Community believe in SYRS or REVB? Syros Pharmaceuticals received 337 more outperform votes than Revelation Biosciences when rated by MarketBeat users. However, 63.83% of users gave Revelation Biosciences an outperform vote while only 63.06% of users gave Syros Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSyros PharmaceuticalsOutperform Votes36763.06% Underperform Votes21536.94% Revelation BiosciencesOutperform Votes3063.83% Underperform Votes1736.17% Does the media prefer SYRS or REVB? In the previous week, Revelation Biosciences' average media sentiment score of 0.00 beat Syros Pharmaceuticals' score of -0.71 indicating that Revelation Biosciences is being referred to more favorably in the news media. Company Overall Sentiment Syros Pharmaceuticals Negative Revelation Biosciences Neutral Do insiders & institutionals have more ownership in SYRS or REVB? 91.5% of Syros Pharmaceuticals shares are held by institutional investors. Comparatively, 12.8% of Revelation Biosciences shares are held by institutional investors. 12.3% of Syros Pharmaceuticals shares are held by insiders. Comparatively, 0.2% of Revelation Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, SYRS or REVB? Syros Pharmaceuticals has a beta of 1.33, suggesting that its share price is 33% more volatile than the S&P 500. Comparatively, Revelation Biosciences has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Is SYRS or REVB more profitable? Revelation Biosciences' return on equity of -193.51% beat Syros Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Syros PharmaceuticalsN/A -3,369.56% -97.04% Revelation Biosciences N/A -193.51%-84.00% Which has higher valuation & earnings, SYRS or REVB? Revelation Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSyros Pharmaceuticals$386K13.90-$164.57M-$3.03-0.07Revelation BiosciencesN/AN/A-$120K-$16.76-0.02 Do analysts prefer SYRS or REVB? Syros Pharmaceuticals currently has a consensus price target of $3.33, indicating a potential upside of 1,566.67%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Syros Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummarySyros Pharmaceuticals beats Revelation Biosciences on 9 of the 15 factors compared between the two stocks. Ad Behind the MarketsWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.Take these 4 steps today to protect your retirement NOW Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio-0.0210.5990.1317.20Price / SalesN/A196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.015.094.784.78Net Income-$120,000.00$151.83M$120.31M$225.60M7 Day Performance-19.44%-2.14%-1.92%-1.23%1 Month Performance-61.59%-4.56%13.65%0.46%1 Year Performance-98.19%8.87%28.34%15.24% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences0.7353 of 5 stars$0.29-7.8%N/A-98.3%$1.35MN/A-0.0210SYRSSyros Pharmaceuticals4.2521 of 5 stars$0.22+5.0%$3.33+1,432.6%-96.5%$5.84M$9.94M-0.07120Gap UpGTBPGT Biopharma3.6571 of 5 stars$2.59-5.8%$11.00+324.7%-78.3%$5.79MN/A0.008Positive NewsGap UpCNSPCNS Pharmaceuticals1.2297 of 5 stars$0.10-2.4%$0.50+398.0%-99.8%$5.77MN/A0.005HOTHHoth Therapeutics2.0095 of 5 stars$0.81flat$3.50+332.1%-30.8%$5.59MN/A-0.614Gap UpPPBTPurple Biotech1.6721 of 5 stars$4.06+6.0%$33.00+712.8%N/A$5.40MN/A-0.4720ELABElevai Labs0.3455 of 5 stars$2.07-9.6%N/A-99.3%$5.36M$2.45M-0.0318News CoverageGap DownCANFCan-Fite BioPharma1.7928 of 5 stars$1.51-4.4%$14.00+827.2%-30.7%$5.35M$667,000.00-0.888IMCCIM Cannabis0.0474 of 5 stars$2.35-4.9%N/A+3.4%$5.25M$51.39M-0.72340Gap DownAEZSAeterna ZentarisN/A$2.90flatN/A-68.1%$5.20M$2.37M-0.2020Analyst ForecastBMRABiomerica0.142 of 5 stars$0.31-2.0%N/A-76.8%$5.17M$5.51M-0.8260Gap Down Related Companies and Tools Related Companies Syros Pharmaceuticals Competitors GT Biopharma Competitors CNS Pharmaceuticals Competitors Hoth Therapeutics Competitors Purple Biotech Competitors Elevai Labs Competitors Can-Fite BioPharma Competitors IM Cannabis Competitors Aeterna Zentaris Competitors Biomerica Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:REVB) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REVB Stock Alerts